The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Doradla Radha Krishna HUF & Others
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Astal Laboratories reported a SEBI SAST Regulation 29(2) disclosure filed by Doradla Radha Krishna on behalf of himself and persons acting in concert (Doradla Radha Krishna HUF, Gandharva Financial Services Pvt Ltd, and Siva Nageswara Rao Doradla), all classified as non-promoters. On 14 January 2026, the company allotted equity shares under a preferential allotment — 775,370 shares to Doradla Radha Krishna HUF and 300,000 shares to Radhakrishna Doradla via conversion of warrants into equity. After the allotment, the group's collective holding stands at 19,10,370 shares, representing 4.53% of the expanded share capital. The company's total equity capital rose sharply from Rs. 10.77 crore (1.07 crore shares) to Rs. 42.22 crore (4.22 crore shares), indicating a large preferential issue, partly via share swap.
This is a non-promoter, non-controlling acquisition through preferential allotment and warrant conversion, so it does not change promoter control. The sharp expansion of equity capital (nearly 4x) may dilute existing shareholders, and investors should watch for the broader terms of the preferential issue and the identity of the new shareholders.